CARMHA Research Seminars

The Benefits and Risks of Attention Deficit Hyperactivity Disorder Medication

Presenter: Dr. Brian D'Onofrio
: July 25, 2019
: 12:00pm - 1:00pm
: SFU Harbour Centre, Room 2200


Randomized controlled trials (RCTs) suggest that attention deficit hyperactivity disorder (ADHD) medication has beneficial short-term effects on symptoms of ADHD, and some co-occurring disorders. RCTs of ADHD medication have serious limitations, however, including the inability to generalize to individuals with serious comorbid problems, study rare-but-serious outcomes, and adequately examine long-term outcomes. Therefore, there is a critical need to more precisely identify the specific benefits and risks of ADHD medication, particularly with samples and designs that can explore rare outcomes. The presentation will provide examples of how the analyses of large-scale health insurance claims datasets in the United States and national registry data (e.g., in Sweden) can help specify the benefits and risks of ADHD medication when using advanced research designs. In particular, the presentation will describe how the use of within-individual comparisons can help elucidate the associations between ADHD medication and numerous outcomes. 

Brief Bio:

Brian D’Onofrio is a Professor and the Director of Clinical Training in the Department of Psychological and Brain Sciences at Indiana University. He received his undergraduate and graduate degrees in Psychology from the University of Virginia, and he completed his internship at Children’s Hospital Boston/Harvard Medical School. His research explores the causes and treatments of behavioral health problems using large-scale, epidemiologic datasets.